Gilead Science announced on February 12 that NASH’s research drug, ASK1 inhibitor selonsertib (GS4997), missed the primary endpoint in its first phase III clinical trial (STELLAR-4). STELLAR-4 is a phase III randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of the NASH new drug selonsertib in patients… Continue Reading Gilead NASH new drug selonsertib first phase III clinical failure

  Two years ago, the University of Basel’s Don Benjanmin research team published an article in the journal Science Advance, saying that the antihypertensive drug syrosingopine (silosepine) significantly enhanced the anti-tumor efficacy of metformin, causing the medical community. Extensive discussion: Metformin plus carbazone is an anticancer drug? But the research… Continue Reading Metformin anticancer mechanism

  Gump’s troubles In 2013, Gump’s actor, the second American movie star Tom Hanks, who won the Oscar for Best Actor Award for two consecutive years, frankly told the hosts and viewers on a nighttime talk show: “When I went to see a doctor, he said to me, ‘Do you… Continue Reading From lizard venom to a new drug for type 2 diabetes – Lyxumia

  Fatty liver has become the most common chronic liver disease in the world. The prevalence of fatty liver in adults in China has exceeded 25%, and one in every 3 adults in Beijing and Shanghai has fatty liver. When B-ultrasound diagnoses fatty liver, do you need medication? What medicine… Continue Reading What drugs can be used for fatty liver?

  The human fertilization process is usually described as a massive swimming marathon, and only the fastest and strongest sperm can win the reward of combining with the egg cells. However, the real process of human fertilization is very different from what people imagine. In this article, the famous biological… Continue Reading The fastest and strongest sperm can be combined with the egg? In fact, it’s luck.

  The future of rindopepimut seems to be bright in 2015. The results of three clinical trials have shown that this peptide tumor therapeutic vaccine can elicit an immune response and delay polymorphic glioblastoma multiforme (GBM). The disease progression of the patient. GBM is the most malignant brain cancer. The… Continue Reading Bronze Age of Glioblastoma Immunotherapy

  For some B-cell-related blood cancers, the efficacy of CAR-T therapy is unquestionable. Last year, the FDA approved two CAR-T therapies, and many pharmaceutical companies began investing a lot of money and manpower in the field. However, the clinical application of CAR-T therapy still faces many obstacles, such as toxicity… Continue Reading New directions for CAR-T treatment: autoimmune disease and graft versus host disease

A variety of tumor immunotherapies that activate T cells are effective in treating many types of cancer. However, due to the existence of the blood-brain barrier, immune cells cannot effectively infiltrate brain tumors, which is also an important reason why immunotherapy is difficult to effect on glioblastoma.   The blood-brain… Continue Reading Successfully cross the blood-brain barrier, will CAR-T become a new breakthrough in the treatment of brain cancer?

  Traditional gene therapy and emerging gene editing therapy for Duchenne Muscular Dystrophy (DMD), which one is better? Some recent research may give us some new thinking.   There are approximately 300,000 DMD patients worldwide. Due to the presence of mutations, patients are unable to produce dystrophin normally, causing atrophy… Continue Reading Traditional gene therapy vs. gene editing, who is the king of DMD treatment?